After a busy few weeks of news about Merck ‘s cancer-drug pipeline, the pharmaceutical company will announce its quarterly financial results on Thursday.
Wall Street analysts expect Merck to report earnings of $1.95 per share for the third quarter, up from $1.85 in the same quarter last year, according to FactSet. They expect sales of $15.3 billion, compared with $15 billion a year earlier. Also last week, Merck disclosed positive data from a number of trials, many involving Keytruda, its megablockbuster cancer immunotherapy. One Merck presentation, saying overall survival was increased by half in patients with urothelial cancer who received Keytruda in combination with the Seagen and Astellas Pharma drug Padcev, “earned a standing ovation,” according to a note from Goldman Sachs analyst Chris Shibutani.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
Trading Earnings Season: 3 Steps for Using Earnings ReportsLearn how to trade earnings season, with tips on choosing companies and researching market conditions to establishing a strategy.
مصدر: DailyFX - 🏆 305. / 63 اقرأ أكثر »
مصدر: WSJ - 🏆 98. / 63 اقرأ أكثر »
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »
مصدر: Investingcom - 🏆 450. / 53 اقرأ أكثر »
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »